India, July 21 -- image credit- freepik

Mumbai-based pharma major Lupin has announced the strategic spin-out of two oncology programmes - LNP7457 (PRMT5) and LNP8701 (SOS1), through its wholly owned subsidiary, Lupin Inc., into Kaveri Therapeutics Inc., a US-based clinical-stage oncology company. Kaveri will advance these programmes through global clinical trials.

Under the terms of the agreement, Lupin Inc. will have a significant equity stake in Kaveri, provide seed funding, and grant them exclusive rights to the programmes.

Kaveri will operate as an independent entity under the leadership of Chief Executive Officer Kristi Jones, a seasoned biopharmaceutical leader with a strong track record of building and advancing innovative compa...